NCT06231381 Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
| NCT ID | NCT06231381 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shanghai Huaota Biopharmaceutical Co., Ltd. |
| Condition | Generalized Pustular Psoriasis (GPP) |
| Study Type | INTERVENTIONAL |
| Enrollment | 33 participants |
| Start Date | 2024-02-29 |
| Primary Completion | 2025-02-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 33 participants in total. It began in 2024-02-29 with a primary completion date of 2025-02-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
Eligibility Criteria
Inclusion Criteria: * Patients must be experiencing an acute GPP flare of moderate-to-severe intensity at baseline, defined as: 1. A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of ≥ 3; 2. New appearance or worsening of existing pustules, and a GPPGA pustulation subscore of ≥ 2; 3. ≥ 5% Body Surface Area (BSA) covered with pustules. * Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug; * Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules. Exclusion Criteria: * Drug-triggered acute generalized exanthematous pustulosis (AGEP); * Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome (SAPHO); * Other active inflammatory or autoimmune diseases requiring systemic treatment with immunosuppressants, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), inflammatory bowel disease, and uveitis. * Patients with an increased risk of infectious complications as assessed by the investigator (e.g., a recent suppurative infection, any congenital or acquired immunodeficiency, such as HIV infection, prior organ or stem cell transplantation); * Patients who have received a live vaccine or investigational live vaccine within 6 weeks prior to the first dose of the study drug, or plan to receive a live vaccine or participate in a clinical study of investigational live vaccine during the study period or within 6 weeks after completion of administration of the study drug; * Patients who have had a serious trauma or undergone a major surgery within 1 month prior to the first dose of the study drug, or plan to undergo any elective surgery during the study period; * Patients with documented active or suspected malignancy or a history of malignancy within 5 years prior to screening; * Patients with a history of severe allergy, who have experienced grade 3-4 allergic reactions when receiving other monoclonal antibodies, or those who are known to have hypersensitivity to protein drugs, recombinant proteins, or HB0034 components; * Subjects who are pregnant or breastfeeding, or those who have a positive pregnancy test result. Breastfeeding female subjects who stop breastfeeding prior to the first dose of the study drug until 16 weeks after the end of the trial will not be excluded; * Patients who are currently participating in clinical trials or have participated in clinical trials of any drug/device within 30 days (or 5 half-lives, whichever is longer) prior to the first dose of the study drug; * Patients expected to have poor compliance, such as those who are uncooperative, fail to receive follow-up on time, and are unlikely to complete the study; * Other reasons that the investigator considers it is inappropriate to participate in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06231381 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Generalized Pustular Psoriasis (GPP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06231381 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06231381 currently recruiting?
Yes, NCT06231381 is actively recruiting participants. Contact the research team at guodong.zhou@huaota.com for enrollment information.
Where is the NCT06231381 trial being conducted?
This trial is being conducted at Beijing, China, Shanghai, China.
Who is sponsoring the NCT06231381 clinical trial?
NCT06231381 is sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. The trial plans to enroll 33 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.